胰康胶囊降血糖作用

目的:探讨胰康胶囊对四氧嘧啶诱发的高血糖大、小鼠模型的降糖作用.方法:尾静脉注射四氧嘧啶72 h造ICR小鼠(85 mg· kg-1)、SD大鼠(60 mg· kg-1)糖尿病模型后,随机分为6组:胰康胶囊高、中、低剂量组,模型对照组,盐酸二甲双胍阳性对照组,金芪降糖片阳性对照组.胰康胶囊小鼠2.8,1.4,0.7 g·kg-1,大鼠2.2,1.1,0.55 g·kg-1剂量下连续ig给药11d后,观察胰康胶囊高、中、低剂量降糖作用以及对正常小鼠葡萄糖耐量的影响.结果:胰康胶囊高、中、低剂量能使高糖模型小鼠血糖值明显降低,与模型组小鼠比较,差异有显著性意义(P＜0.01).降糖百分率分别为23.8％,21.1％,18.7％；胰康胶囊在给药11d和停药24 h能显著抑制高糖模型大鼠血糖升高；胰康胶囊对正常小鼠的葡萄糖耐量有明显改善作用.结论:胰康胶囊对四氧嘧啶所致高血糖小鼠、大鼠血糖值有明显降低作用；对正常小鼠的糖耐量有显著的改善作用.

The Hypoglycemic Action by Yikang Capsules

Objective: To study the hypoglycemic effect of Yikang capsules in the diabetic mouce and rat model. Method: Alloxan were injected in ICR mice (85 mg·kg^-1) and SD rats (60 mg·kg^-1) by Intravenous injection, then the diabetic model was established after 72 h. ICR mice and SD rats were divided into seven groups randomly, Yikang capsules high, medium and low dose groups, control group, model control group,positive control group (metformin hydrochloride),Jinqi tablet control group. and corresponding drugs were given for 11 days, then the glucose tolerance was observed. Result: Yikang capsules high, medium and low-dose showed hypoglycemic action in diabetic ICR mice. Compared with the model group, there was significant difference in blood glucose level(P<0.01). Hypoglycemic percentage was 23.8%, 21.1%and 18.7%, respectively. Yikang capsules could significantly inhibit the increased blood glucose at the day 11 of administration and at 24 hours of withdrawal; Yikang capsules could improve the glucose tolerance of the normal mice. Conclusion: Yikang capsules has a hypoglycemic action in diabetic ICR mouce and rat model induced by alloxan, and can improve the glucose tolerance of normal mice.